Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 619 GBX Market Closed
Market Cap: 745.9m GBX

Oxford BioMedica PLC
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Oxford BioMedica PLC
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Oxford BioMedica PLC
LSE:OXB
Net Income (Common)
-ÂŁ37.1m
CAGR 3-Years
-15%
CAGR 5-Years
-24%
CAGR 10-Years
-14%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Net Income (Common)
-$235.8m
CAGR 3-Years
15%
CAGR 5-Years
-116%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Net Income (Common)
-$250.7m
CAGR 3-Years
-35%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Net Income (Common)
-ÂŁ51.1m
CAGR 3-Years
27%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Net Income (Common)
ÂŁ19.3m
CAGR 3-Years
-22%
CAGR 5-Years
-11%
CAGR 10-Years
-7%
Avacta Group PLC
LSE:AVCT
Net Income (Common)
-ÂŁ58.1m
CAGR 3-Years
-34%
CAGR 5-Years
-35%
CAGR 10-Years
-19%
No Stocks Found

Oxford BioMedica PLC
Glance View

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

OXB Intrinsic Value
543.1 GBX
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Oxford BioMedica PLC's Net Income (Common)?
Net Income (Common)
-37.1m GBP

Based on the financial report for Jun 30, 2025, Oxford BioMedica PLC's Net Income (Common) amounts to -37.1m GBP.

What is Oxford BioMedica PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-14%

Over the last year, the Net Income (Common) growth was 74%. The average annual Net Income (Common) growth rates for Oxford BioMedica PLC have been -15% over the past three years , -24% over the past five years , and -14% over the past ten years .

Back to Top